Corient Private Wealth
KYNB

Corient Private Wealth’s Kyntra Bio KYNB Stock Holding History

Corient Private Wealth’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,013
Closed -$87.9K – 2885
2025
Q4 		$87.9K Buy
+10,013
New +$97.9K ﹤0.01% 2565
2025
Q2 		– Sell
-4,084
Closed -$31.6K – 2474
2025
Q1 		$31.6K Hold
4,084
– – ﹤0.01% 2245
2024
Q4 		$54.1K Hold
4,084
– – ﹤0.01% 2275
2024
Q3 		$40.8K Hold
4,084
– – ﹤0.01% 2412
2024
Q2 		$91.1K Hold
4,084
– – ﹤0.01% 2220
2024
Q1 		$240K Hold
4,084
– – ﹤0.01% 2014
2023
Q4 		$90.5K Sell
4,084
-38
-0.9% -$573 ﹤0.01% 2164
2023
Q3 		$88.9K Buy
+4,122
New +$162K ﹤0.01% 2039

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Corient Private Wealth's KYNB Position: Q1 2026 in Review

Corient Private Wealth sold out of Kyntra Bio (KYNB) in Q1 2026, closing a stake of 10,013 shares — an estimated $87.9K sold.

Corient Private Wealth first reported a position in KYNB in Q3 2023 and held it in 8 quarters. The position peaked at $240K in Q1 2024. 32 funds tracked by Wall St. Rank hold KYNB as of Q1 2026.

  • Corient Private Wealth reported no remaining Kyntra Bio position as of Q1 2026 after selling out during the quarter.
  • Corient Private Wealth sold 10,013 Kyntra Bio shares in Q1 2026, an estimated $87.9K.
  • Corient Private Wealth first reported a position in Kyntra Bio in Q3 2023 and held it in 8 quarters.
  • Corient Private Wealth's Kyntra Bio position peaked at $240K in Q1 2024.
  • 32 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.